|
|
Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON-HF trial
Lars H. Lund
,
Gianluigi Savarese
,
Ashwin Venkateshvaran
,
Lina Benson
,
Anna Lundberg
et al.
Journal articles
hal-03463825v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Long-term outcomes in heart failure with preserved ejection fraction: Predictors of cardiac and non-cardiac mortality
Angiza Shahim
,
Marion Hourqueig
,
Lars H Lund
,
Gianluigi Savarese
,
Emmanuel Oger
et al.
Journal articles
hal-04055957v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Changes in natriuretic peptides after acute hospital presentation for heart failure with preserved ejection fraction: A feasible surrogate trial endpoint? A report from the prospective Karen study
Gianluigi Savarese
,
Erwan Donal
,
Camilla Hage
,
Emmanuel Oger
,
Hans Persson
et al.
Journal articles
hal-01446557v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Prognostic impact of Framingham heart failure criteria in heart failure with preserved ejection fraction
Lars H Lund
,
Ulrika Löfström
,
Camilla Hage
,
Gianluigi Savarese
,
Erwan Donal
et al.
Journal articles
hal-02178715v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Predictors of long-term outcome in heart failure with preserved ejection fraction: a follow-up from the KaRen study
Angiza Shahim
,
Marion Hourqueig
,
Erwan Donal
,
Emmanuel Oger
,
Ashwin Venkateshvaran
et al.
Journal articles
hal-03329641v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Changes in natriuretic peptides after acute hospital presentation for heart failure with preserved ejection fraction A feasible surrogate trial endpoint? A report from the prospective Karen study (vol 226, pg 65, 2017)
Gianluigi Savarese
,
Erwan Donal
,
Camilla Hage
,
Emmanuel Oger
,
Hans Persson
et al.
Journal articles
hal-01806802v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|